

Initiatives/External Evaluation/Third-party Opinion

Initiatives



United Nations Global Compact

Renewable Energy 100
Declaration RE Action

External Evaluation

FTSE Blossom
Japan Index

FTSE Blossom Japan Index

FTSE Blossom
Japan Sector
Relative IndexFTSE Blossom Japan Sector
Relative Index

S&P/JPX Carbon Efficient Index

2024
健康経営優良法人
Health and productivity
ホワイト500Recognized as White 500 enterprise
under 2024 Certified Health &
Productivity Management Outstanding
Organizations Recognition Program

健康優良企業

Received Healthy Company
Declaration Gold Certificate

Kurumin Certification



Telework Pioneer

Top Hundred Telework
Pioneers Certification

★★★ 2024

Nikkei Smart Work
Management SurveyThe Nikkei SDGs Management
Survey 2023"Most Liked!" IR Award of the
2023 IR Award winnersNikko Investor Relations Co., Ltd.,
All Japanese Listed Companies'
Website Ranking 2023
All Markets Ranking in Japan
AAA Corporate WebsiteGomez IR Website Ranking 2023
Bronze Prize

Third-party Opinion

See the Company's website for third-party opinion.
<https://www.aska-pharma-hd.co.jp/english/csr/opinion.html>

Editorial Postscript

Thank you for reading ASKA HD Report 2024. In this report, we articulated our corporate message of "For a healthy tomorrow and future" and detailed the Company's efforts to resolve health issues and build a sustainable society through messages from each of our executives and employees.

We calculated the value created through our new project of addressing the "Annual Labor Loss due to Women's Menstrual Symptoms" and demonstrated in detail our social contribution to women's medical care. We also held a "Round-table Discussion

with Outside Directors," inviting them to discuss current initiatives and challenges for shaping the Company's future.

We hope that this report has helped you better understand the Group's efforts. We will continue to value opportunities for engaging with our stakeholders as we strive to enhance our information disclosure.

Corporate Communication Section
Corporate Planning Department
ASKA Pharmaceutical Holdings